ArticleDiabetes2017
Identification of RUNX1 as a Mediator of Aberrant Retinal Angiogenesis.
Abstract read
In one paragraph
Article in Diabetes, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 69 papers.
0numbers the graph read from it
0cells of the map it votes in
69citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
69 citing papers in PubMed.
- Article
- An atlas of cGAS-STING signaling in pathophysiological angiogenesis and retinal vascular homeostasis across species.Molecular therapy. Nucleic acids · 2026Article
- An APE1 Redox Inhibitor Attenuates Pathological Retinal Vascularization by Suppressing FGF2 Angiogenic Signaling.Investigative ophthalmology & visual science · 2026Article
- RUNX1 is expressed in a subpopulation of dermal fibroblasts and is associated with disease severity of systemic sclerosis.Annals of the rheumatic diseases · 2026Article
- Ectopic endometrial mesenchymal stem cell-derived exosomal miR-4466 promotes angiogenesis by targeting RUNX1 in adenomyosis.Biochemistry and biophysics reports · 2026Article
- Nanoplastics amplify 6PPD ocular toxicity in zebrafish.Environmental science and ecotechnology · 2026Article
- Methylglyoxal hampers the angiogenic capacity of human retinal endothelial cells modifying cell transcriptome with the contribution of NRSF/REST.Frontiers in cell and developmental biology · 2026Article
- Downregulated miR-199a-3p in Preeclamptic Placenta-derived Exosomes from Cord Blood Hinders VEGF-induced Fetal Glomerular Dysplasia Through Inhibiting Akt1(S473) Phosphorylation via Targeting PHLPP2.Stem cell reviews and reports · 2025Article
- P300 Promotes RUNX1 Transcription to Regulate Autophagy and Drive Corneal Neovascularization.Investigative ophthalmology & visual science · 2025Article
- Cathepsin H increases the risk of diabetic retinopathy: evidence from Mendelian randomization and bioinformatic analysis.Diabetology & metabolic syndrome · 2025Article
- Ref-1 redox activity modulates canonical Wnt signaling in endothelial cells.Redox biology · 2025Article
- CAVIN3 deficiency promotes vascular normalization in ocular neovascular disease via ERK/JAG1 signaling pathway.JCI insight · 2025Article
- Targeted siRNA Delivery Against RUNX1 Via tFNA: Inhibiting Retinal Neovascularization and Restoring Vessels Through Dll4/Notch1 Signaling.Investigative ophthalmology & visual science · 2025Article
- Fibronectin Mediates Endothelial-to-Mesenchymal Transition in Retina Angiogenesis.Investigative ophthalmology & visual science · 2025Article
- Ref-1 redox activity regulates retinal neovascularization by modulating transcriptional activation of HIF-1α.FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2025Article
- Gene and phenome-based analysis of the shared genetic architecture of eye diseases.American journal of human genetics · 2025Article
- Targeting Runx1 in Pathological Retinal Angiogenesis: A Potential Therapeutic Approach.Investigative ophthalmology & visual science · 2025Article
- Progress in Nanotechnology for Treating Ocular Surface Chemical Injuries: Reflecting on Advances in Ophthalmology.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Review
- Lipoxin A4 (LXA4) as a Potential Drug for Diabetic Retinopathy.Medicina (Kaunas, Lithuania) · 2025Review
- YBX1-driven TUBB6 upregulation facilitates ocular angiogenesis via WNT3A-FZD8 pathway.Theranostics · 2025Article
9 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors.
Jonathan D LamDepartment of Ophthalmology, Schepens Eye Research Institute/Massachusetts Eye and Ear, Harvard Medical School, Boston, MA.
Daniel J OhDepartment of Ophthalmology, Schepens Eye Research Institute/Massachusetts Eye and Ear, Harvard Medical School, Boston, MA.
Lindsay L WongDepartment of Ophthalmology, Schepens Eye Research Institute/Massachusetts Eye and Ear, Harvard Medical School, Boston, MA.
Dhanesh AmarnaniDepartment of Ophthalmology, Schepens Eye Research Institute/Massachusetts Eye and Ear, Harvard Medical School, Boston, MA.
Cindy Park-WindholDepartment of Ophthalmology, Schepens Eye Research Institute/Massachusetts Eye and Ear, Harvard Medical School, Boston, MA.
Angie V SanchezDepartment of Ophthalmology, Schepens Eye Research Institute/Massachusetts Eye and Ear, Harvard Medical School, Boston, MA.
Jonathan Cardona-VelezDepartment of Ophthalmology, Schepens Eye Research Institute/Massachusetts Eye and Ear, Harvard Medical School, Boston, MA.
Declan McGuoneC.S. Kubik Laboratory for Neuropathology, Massachusetts General Hospital, Boston, MA.
Anat O Stemmer-RachamimovC.S. Kubik Laboratory for Neuropathology, Massachusetts General Hospital, Boston, MA.
Dean EliottRetina Service, Department of Ophthalmology, Massachusetts Eye and Ear, Harvard Medical School, Boston, MA.
Diane R BielenbergVascular Biology Program, Department of Surgery, Boston Children's Hospital, Harvard Medical School, Boston, MA.
Tave van ZylRetina Service, Department of Ophthalmology, Massachusetts Eye and Ear, Harvard Medical School, Boston, MA.
Lishuang ShenCenter for Personalized Medicine, Children's Hospital Los Angeles, Los Angeles, CA.
Xiaowu GaiCenter for Personalized Medicine, Children's Hospital Los Angeles, Los Angeles, CA.
Patricia A D'AmoreDepartment of Ophthalmology, Schepens Eye Research Institute/Massachusetts Eye and Ear, Harvard Medical School, Boston, MA joseph_arboleda@meei.harvard.edu leo_kim@meei.harvard.edu patricia_damore@meei.harvard.edu.
Leo A KimDepartment of Ophthalmology, Schepens Eye Research Institute/Massachusetts Eye and Ear, Harvard Medical School, Boston, MA joseph_arboleda@meei.harvard.edu leo_kim@meei.harvard.edu patricia_damore@meei.harvard.edu.
Joseph F Arboleda-VelasquezDepartment of Ophthalmology, Schepens Eye Research Institute/Massachusetts Eye and Ear, Harvard Medical School, Boston, MA joseph_arboleda@meei.harvard.edu leo_kim@meei.harvard.edu patricia_damore@meei.harvard.edu.
Funding
VISION RESEARCHP30EY003790 · NEI · SCHEPENS EYE RESEARCH INSTITUTE · PI Sunil K Chauhan · 1985 to 2026
$25.5MMass Eye and Ear-Vision Clinical Scientist Development ProgramK12EY016335 · NEI · MASSACHUSETTS EYE AND EAR INFIRMARY · PI Reza Dana · 2004 to 2026
$12.3MTHE ROLE OF MICROVASCULAR CELLS IN NEOVASCULARIZATIONR01EY005318 · NEI · SCHEPENS EYE RESEARCH INSTITUTE · PI D'AMORE, PATRICIA ANN · 1985 to 2015
$6.4MThe neuropilin 2 axis in smooth muscle contractilityR01DK104641 · NIDDK · BOSTON CHILDREN'S HOSPITAL · PI ADAM, ROSALYN M, BIELENBERG, DIANE RENEE · 2016 to 2020
$2.4MNotch and TGF-beta in the Control of Retinal Vascular IntegrityR00EY021624 · NEI · SCHEPENS EYE RESEARCH INSTITUTE · PI ARBOLEDA-VELASQUEZ, JOSEPH · 2014 to 2016
$736kVasculogenesis in Thyroid Eye DiseaseR21EY027061 · NEI · SCHEPENS EYE RESEARCH INSTITUTE · PI KIM, LEO A · 2016 to 2017
$542kExploring the Role of Aging in Cerebral Ischemic Small Vessel Disease Using Notch3 Mutant MiceUH2NS100121 · NINDS · SCHEPENS EYE RESEARCH INSTITUTE · PI ARBOLEDA-VELASQUEZ, JOSEPH · 2016 to 2017
$277kHoward Hughes Medical InstituteNEI NIH HHS K12 EY016335NEI NIH HHS P30 EY003790NEI NIH HHS R00 EY021624NEI NIH HHS R01 EY005318NEI NIH HHS R21 EY027061NIDDK NIH HHS R01 DK104641NINDS NIH HHS UH2 NS100121
Abstract
Proliferative diabetic retinopathy (PDR) is a common cause of blindness in the developed world's working adult population and affects those with type 1 and type 2 diabetes. We identified Runt-related transcription factor 1 (RUNX1) as a gene upregulated in CD31
Indexed as
AdultAgedAged, 80 and overAnimalsCell MovementCell ProliferationCore Binding Factor Alpha 2 SubunitDiabetes Mellitus, Type 1Diabetes Mellitus, Type 2Diabetic RetinopathyDisease Models, AnimalEndothelial CellsFemaleGlucoseHumansImmunohistochemistryCore Binding Factor Alpha 2 SubunitGlucoseOxygenRNA, MessengerRUNX1 protein, humanRunx1 protein, mouse
Identifiers
What OpenQuestion holds
Textmetadata
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.